Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INV-347 · 1 trial · 1 indication
Number of events
| Arm | Type | Description |
|---|---|---|
| Participants from the study INV-CL-108 | EXPERIMENTAL | Participants who were dosed with INV-347 in the First In Human study INV-CL-108 and still have measurable plasma exposure of INV-347 are included to assess long term safety. |
| Name | Type | Description |
|---|---|---|
| INV-347 | DRUG | Participants who were dosed with INV-347 in the First In Human study INV-CL-108 and still have measurable plasma exposure of INV-347 are included to assess long term safety. |
Inclusion Criteria: 1. Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. 2. Male or female (sex at birth). 3. Age 18 years or above at the...
Top 20 of 32 competitors
INV-347 is an investigational small molecule being developed for the treatment of obesity. It is currently in Phase 1 clinical development and is being studied in a safety follow-up trial in Canada. The drug is not yet approved and remains under investigation.
INV-347 is being developed by Novo Nordisk A/S, a biopharmaceutical company listed on the stock exchange under the ticker NVO. The company is conducting clinical trials to evaluate the safety and tolerability of this investigational small molecule for obesity.
INV-347 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. A Phase 1 safety follow-up study is currently recruiting participants in Canada to further evaluate the drug's safety profile.
INV-347 is being studied in a Phase 1 clinical trial with the identifier NCT07153172. This trial is a safety follow-up study of participants previously dosed with INV-347, enrolling 91 participants with obesity. The study is currently recruiting in Canada and is not randomized or blinded.
INV-347 is a small molecule, but its specific molecular target has not been disclosed. As a small molecule, it is designed to be taken orally and to interact with biological pathways involved in obesity, though the exact mechanism of action is not publicly detailed at this time.